Steatotic Liver Disease (SLD) is proposed to be the most prevalent liver disease Worldwide due to the close association with the metabolic syndrome and epidemic of obesity and type 2 diabetes. End-stage liver disease, development of hepatocellular carcinoma and increased risk of cardiovascular disease warrants a pro-active holistic approach to the patient with SLD. With this EASL School of Hepatology focused on SLD we will provide an in-depth update on the pathogenesis, screening and treatment of SLD including co-morbidities. The school will provide state of the art presentations by experts in the field and with strong interactions by participants. The participants are expected to be able to implement their new knowledge in order to improve the care of patients with SLD.

School Organisers: Jacob George, Henning Gronbaek and Karen Louise Thomsen.

This EASL School will provide knowledge and a better understanding of:

• Steatotic Liver Disease pathogenesis
• Steatotic Liver Disease treatments
• Steatotic Liver Disease follow-up including co-morbidites

• Hepatologists
• Clinical scientists (phD-students and postdocs)
• Paediatric Hepatologists with interest in steatotic liver disease

• State of the art update on the pathogenesis of Steatotic Liver Disease
• To get updated on management of Steatotic Liver Disease from treatment to follow-up
• To increase your network of young clinicians, investigators and the expert faculty in Steatotic Liver Disease

This EASL School is supported by Novo Nordisk. Novo Nordisk has had no input into the content of this EASL School.